Document:

Offer Letter

 Exhibit 10.11 

 
 

 
 October 15, 2007 
 William D. Waddill 
 [Address] 
 Dear William, 
 It gives me great pleasure to offer you the position of Senior Vice President and
Chief Financial Officer of OncoMed Pharmaceuticals, Inc. (“OncoMed” or “the Company”). 
 The terms of our offer to you are
as follows: 
  

			
	Title:	 	Senior Vice President and Chief Financial Officer
		
	Reporting to:	 	Paul J. Hastings, President & CEO
		
	Base Salary:	 	Your Base Salary will be $22,916.66 per month (a $275,000 annualized rate), payable in accordance with customary Company payroll procedures then in effect for others employed by the
Company, subject to review on an annual basis.
		
	Annual Bonus:	 	Bonus eligibility up to 25% of your base salary. This Bonus will be based upon achievement of (1) corporate goals and (2) specific department and personal goals to be agreed to by
the President & CEO.
		
	Stock Options	 	Subject to final approval of the Board, you will be granted an option to purchase 575,000 shares of common stock of Company (the “Option”). At your request, the Option
shall be an incentive stock option to the maximum extent permitted under the applicable federal income tax rules and shall have an exercise price equal to the fair market value of Company’s stock as of the date the Option is granted. Subject to
your remaining continuously employed by Company as of each such date the Option shall vest and become exercisable with respect to 20% of the

  

					
	800 Chesapeake Drive    Redwood City, CA 94063    Phone: 650-995-8200    Fax:
650-298-8600    www.oncomed.com
			
	William Waddill Offer Oct 15, 2007	 	- 1 -	 	

			
		 	shares subject to the Option on the first anniversary of your commencement of employment, and shall become vested in equal monthly installments thereafter, such that the Option is
vested and exercisable with respect to 100% of the shares subject to the Option on the fifth anniversary of the Option’s date of grant. The specific terms of the Option grant will be set forth in a written Stock Option Agreement between you and
the Company which will be executed after your employment commences with Company. You will also be eligible for additional stock option grants, based on your performance, and as part of general company practices.
		
	Change of Control	 	In the event of a “Change In Control” (as defined in the OncoMed Pharmaceuticals, Inc. Stock Incentive Plan), the vesting of an additional 12 months of any then-unvested
shares or stock options will be accelerated. The balance will continue to vest at the same monthly rate as they would have vested if no such acceleration had occurred. In addition, in the event that you are terminated without “Cause” or
terminate your own employment for “Good Reason” (as defined below) within eighteen months after a “Change in Control,” 100% of any shares or stock options which are not vested at the time of your termination will accelerate and
become vested. In the event of termination without “Cause” or for “Good Reason” your Base Salary will continue for six months and your basic employee benefits for twelve months. Payments will be made during the continuation
period according to the Company’s normal payroll policy. Receipt of the salary and benefits provided to you under this paragraph will be conditioned on your executing a standard form of release of the Company and associated persons from any
claims against the Company and such associated persons, and subject to mitigation obligations. In this context “Cause” shall mean (i) your gross negligence, willful misconduct, or repeated, willful and flagrant insubordination in the
performance of your

  
 2 

			
		 	duties to the Company as directed by the Board which remains uncured more than thirty days following written notice from the Board of its belief that there is Cause for your
termination under this clause (i); (ii) repeated unexplained or unjustified absence from the Company; (iii) a material and willful commission of any federal or state felony; (iv) commission of any act of fraud with respect to the Company; or (v)
conviction of a felony or a crime involving moral turpitude causing material harm to the standing and reputation of the Company , or any willful violation of a Federal or State law that significantly reduces the credibility of the company, or
affects the company in a materially financial way. No act or failure to act by you shall be deemed “willful” if done or omitted to be done by you in good faith and with the reasonable belief that your act or omission was in the best
interest of the Company or consistent with the Company’s policies or the directive of the Board. For purposes of this letter agreement, “Good Reason” shall mean your termination of your employment following a Change in Control by
reason of the material diminution of your duties and responsibilities (such as the loss of oversight as Chief Financial Officer or the senior officer responsible for financial and administration of the Company’s operations such that your
overall responsibilities are materially reduced), the reduction of your overall compensation other than as a part of a general reduction for all executive officers, or the transfer of your principal place of business for the Company more than 10
miles south or west, or 50 miles north or east from the Company’s current Redwood City, California location.
		
	Vacation:	 	In accordance with Company policy.
		
	Benefit Plans:	 	You shall be entitled to the Company’s basic employment benefits available to all Company employees, as the same currently exists or may exist in the future. You acknowledge
that participation in Company benefit programs

  
 3 

			
		 	may require payroll deductions and/or direct contributions by you.
		
	At Will:	 	The Company’s employees serve on an at-will basis. Your employment is voluntarily and for no set period. If you accept employment with the Company, you will be free to resign
at any time. Likewise, the Company will be free to terminate your employment at any time, with or without good cause or for any or no cause.
		
	Employment Terms:	 	This offer of employment is contingent upon your signing and returning to the Company on or before your employment start date, the Company’s standard form of “Confidential
Information and Invention Assignment Agreement.” That agreement provides, among other things, that you will not solicit employees of the Company for a period of one year following termination of your employment by the Company for any reason. In
addition, you will not accept any additional outside business responsibilities (such as serving on the Board of Directors of other companies) without the prior approval of the President and CEO of OncoMed.
		
	Expenses:	 	The Company will reimburse reasonable business-related expenses incurred by you in accordance with applicable Company policies.
		
	Start Date:	 	As soon as practicable, at your election, but in no event later than October 29, 2007. Please be advised that your employment is contingent on your ability to prove your
authorization to work in the United States. You must comply with the Immigration and Naturalization Service’s employment verification requirements.

 Please note that this offer letter sets forth the entire agreement and understanding between you and the Company
regarding your employment relationship and supersedes any other written or oral representation, promise or discussion. 
 To indicate your
acceptance of this offer, please sign and return one copy of this letter to me. Will, we are very much looking forward to having you as Senior Vice President and Chief Financial Officer. 

  
 4 

 Yours very truly, 
 /s/ Paul J. Hastings 
 Paul J. Hastings 
 President and Chief Executive Officer 
 OncoMed Pharmaceuticals, Inc. 

By accepting this offer you agree this is a full-time position, and you will make every effort necessary to perform adequately the duties that are
assigned to you. 
 Agreed to and accepted: 
  

							
	 /s/ William D. Waddill
	 		 	 10/15/07
	 	
	William D. Waddill	 		 	Date	 	

  
 5Offer Letter

 Exhibit 10.12 

 
 

 
 June 18, 2009 
 Sunil Patel 
 [Address] 
 Dear Sunil, 
 It gives me great pleasure to offer you the position of Senior Vice President,
Corporate Development of OncoMed Pharmaceuticals, Inc. (“OncoMed” or “the Company”). 
 The terms our offer to you are as
follows: 
  

	 	•	 	 Title: Senior Vice President, Corporate Development 

 

	 	•	 	 Reporting to: Paul J. Hastings, President and Chief Executive Officer 

 

	 	•	 	 Start Date: Your employment with the Company will commence on July 6, 2009. 

 

	 	•	 	 Base Salary: Your annual salary will be $285,000 per year, payable in accordance with customary Company payroll procedures then in effect for
others employed by the Company, subject to review on an annual basis. 

  

	 	•	 	 Annual Bonus: Bonus eligibility up to 25% of your base salary (the “Target Bonus”). This Bonus will be based upon achievement of
(1) corporate goals and (2) specific department and personal goals to be agreed to by the President and Chief Executive Officer. 

  

	 	•	 	 Benefits: Full time employees of OncoMed are eligible to participate in the OncoMed Health and Dental Care program. Full time employees are
likewise eligible for 15 days of paid time off per year. 

  

	 	•	 	 Stock Options: Subject to the approval of the Board, you will be granted an option to purchase 972,190 shares of common stock of Company (the
“Option”). At your request, the Option shall be an incentive stock option to the maximum extent permitted under the applicable federal income tax rules and shall have an exercise price equal to the fair market value of Company’s stock
as of the date the Option is granted. Subject to your remaining continuously employed by Company as of each such date the Option shall vest and become exercisable with respect to 20% of the shares subject to the Option on the first anniversary of
your commencement of employment, and shall become vested in equal monthly installments thereafter, such that the Option is vested and exercisable with respect to 100% of the shares subject to the Option on the fifth anniversary of the Option’s
date of grant. The specific 

  
 800 Chesapeake
Drive    Redwood City, CA 94063    Phone: 650-995-8200    Fax: 650-298-8600    www.oncomed.com 

	 	 
terms of the Option grant will be set forth in a written Stock Option Agreement between you and the Company which will be executed after your employment commences with Company. You will also be
eligible for additional stock option grants, based on your performance, and as part of general company practices. 

 Additional Performance Option Grant: Subject to the approval of the Board, you will be granted an option to purchase 277,768 shares of common stock of the Company (the “Performance
Option”), which shall commence vesting, if at all, upon the achievement of certain performance goals with respect to material Company agreements and/or strategic Company transactions as shall be established by the Board (the “Performance
Goals”). Following satisfaction of the Performance Goals, the Performance Option will vest according to the Company’s standard five year vesting schedule and shall have an exercise price equal to the fair market value of Company’s
stock as of the date the Performance Option is granted. The specific terms of the Option grant will be set forth in a written Stock Option Agreement between you and the Company which will be executed after your employment commences with Company and
the Board approves the Option grant. 
  

	 	•	 	 Change in Control and Severance: Following your commencement of employment with the Company, you will be able to enter into the Company’s
standard executive form of Change in Control and Severance Agreement which, subject to its terms and conditions, shall provide you with the following benefits: 

In the event of a “Change in Control”, the vesting of any then-unvested shares or stock options will be accelerated by 25% of
the total number of shares subject thereto. The balance will continue to vest at the same monthly rate as they would have vested in if no such acceleration had occurred. In addition, in the event that your employment is terminated by the Company
without “Cause” or you terminate your own employment with the Company for “Good Reason”, within eighteen months after a “Change in Control,” 100% of any shares or stock options which are not vested at the time of your
termination will accelerate and become vested. 
 In the event of termination without “Cause” or for “Good
Reason” you will receive your Base Salary and basic employee benefits for twelve months as well as a proration of your Target Bonus provided this termination occurs within 12 months following a Change in Control. Should the termination without
“Cause” or for “Good Reason” not occur during the 12-month period commencing on a Change in Control, your Base Salary will continue for six months. Payments will be made during the continuation period according to the
Company’s normal payroll policy. Receipt of the salary and benefits provided to you under this paragraph will be conditioned on your executing a standard form of release of the Company and associated persons from any claims against the Company
and such associated persons. 

  
 2 

	 	•	 	 At Will Employment: The Company’s employees serve on an at-will basis. Your employment is voluntary and for no set period. If you accept
employment with the Company, you will be free to resign at any time. Likewise, the Company will be free to terminate your employment at any time, with or without good cause or for any or no cause. 

 

	 	•	 	 Company Rules: As an employee of the Company, you will be expected to abide by company rules and regulations. As a condition of employment, you
will be required to sign and comply with a confidential information and invention assignment agreement which, among other things, prohibits unauthorized use or disclosure of Company’s proprietary information. 

 

	 	•	 	 No Bar to Employment: You agree that you are not party to any contract or agreement that would preclude you from accepting this offer or
performing services as an employee for Company. As required by law, this offer is subject to satisfactory proof of your right to work in the United States. 

 

	 	•	 	 Final Agreement: The employment terms in this letter supersede any other agreements or promises made to you by anyone, whether oral or written,
and comprise the final, complete and exclusive agreement between you and Company. 

 We are very enthusiastic that you have
agreed to join the Company team and we look forward to working with you. The terms of this offer will expire on June 12, 2009. 
  

					
	Sincerely,	 		 	Agreed and accepted:
			
	/s/ Paul J. Hastings	 		 	 /s/ Sunil Patel

	Paul J. Hastings	 		 	Sunil Patel
	President and Chief Executive Officer	 		 	 6/18/09

	OncoMed Pharmaceuticals, Inc.	 		 	Date

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]